A market sophistication rating system for mass tort campaigns. The framework for reading risk, maturity, and capital fit across the litigation landscape — at the tort, defendant, and facility level.
Every mass tort campaign rides two curves simultaneously. Nobody in litigation finance has thought to overlay them, so nobody has the language to price them.
The first is the advertising sophistication curve. As a market matures, the audience gets more skeptical. The same message that converted for pennies in month one costs ten times as much in month twelve. Creative fatigues. Audiences saturate. Costs rise.
The second is the litigation lifecycle curve. As a tort matures, MDLs consolidate, bellwethers resolve, settlement frameworks crystallize, defendants move into resolution posture. Time to cash compresses.
These curves move in opposite directions and they are the same curve. A cheap lead in an emerging tort implies a long road to monetization. An expensive lead in a mature tort implies the market is already in motion. Cost per signed case in isolation is a meaningless number. Cost per signed case plus stage is a real signal of where a market sits and what should be expected from it.
TT Stage is the rating that puts them together.
First to market → promise war → mechanism → identification → new channels. Each stage requires a different creative play and carries a different cost floor. Most campaigns fail because they bring Stage 2 creative to a Stage 4 audience.
Discovery → MDL formation → bellwether → settlement framework → resolution. Each stage compresses time to monetization and improves the knowability of case value. Late-stage torts pay faster against known matrices.
TT Stage assigns every active mass tort campaign a rating from 1 to 5. The rating defines expected creative play, expected cost range, expected time to monetization, and the capital profile that should be deploying into it.
The campaign is telling survivors something nobody else is telling them. The hook is the claim itself. Generic creative converts because novelty is the differentiator. Lowest cost per signed case of any stage.
The risk is not cost. The risk is time and uncertainty. The MDL has not formed. Defendants have not engaged. Some Stage 1 torts die before they monetize. Requires patient capital and a long horizon.
Competitors arrive. To stand out, every firm escalates the promise: largest settlements, fastest process, most aggressive representation. The audience is still responsive but the auction is tightening and CPL begins to climb.
The MDL is forming. Early filings are on record. Discovery is underway. The tort is proving it will monetize. This is the window to establish position before the market becomes efficient and the math becomes public.
Promises stop working because everyone has them. The winner becomes whoever explains the mechanism best: how the case is built, why this firm wins, what the process looks like. Ads become educational. Landing pages, funnels, and trust signals matter more than headlines.
The MDL is consolidated. Bellwethers are scheduled. Case values begin to telegraph from early settlements. This is the fat middle: the tort is validated, the math is knowable, and the downside is contained. Most institutional litigation capital belongs here.
The audience is saturated and skeptical. They have seen fifty ads for this tort. Generic messaging is dead. The winner is whoever the survivor identifies with: specific facilities, real stories, the attorney's own voice, long-form testimonial content. CPM stays flat because no new auction entrants are arriving — but CPL rises because the audience is tired.
Settlement matrices are emerging. Defendants are in resolution posture. The market is moving toward compression on the attorney side — bellwether momentum, framework talks, reduced discovery runway. Capital that wants a shorter, more predictable return profile belongs here and will pay for the certainty.
Settlement framework is published. Payment timelines are known. The defendant is in check-writing mode. This is not a dead campaign — it is the opposite. It is the closing window. Advertising is expensive because every sophisticated buyer is trying to catch the last wave, and new creative angles require real investment and controlled experiments.
The market is in its resolution window. Cases signed at this stage are moving against a known framework rather than through discovery. CPSC looks brutal on a spreadsheet and makes different sense on a risk-adjusted basis. Capital that wants cash velocity, not discovery, belongs here.
A corporate credit rating operates at three levels at once. There is a sector view, an issuer view, and an instrument view. A single bond can carry a different risk profile than its issuer, which can carry a different profile than its sector. All three are true simultaneously. The grain you care about depends on the decision you are making.
TT Stage works the same way. Every tort is rated at three nested levels, and they do not always agree. A tort-level rating reads the category. A defendant-level rating reads the litigation arc. A facility-level rating reads the operational market — creative fatigue, audience saturation, unit economics.
This is the layer where the real decisions get made, and it is the layer no outside observer can see. The LexGenius of the world can tell you a tort exists. They cannot tell you which defendants inside it are in motion, or which facilities inside those defendants have saturated creative and which are still fresh.
The top-line rating that rolls up from everything underneath. Tells a capital allocator whether to enter the category at all, and what to expect from it in aggregate. This is what gets compared across the opportunity board.
Each defendant class inside a tort carries its own rating because each defendant sits at a different point in the litigation lifecycle. Two defendants in the same tort can be stages apart based on MDL status, settlement posture, and financial exposure.
Each facility inside a defendant class has its own ad saturation, its own creative fatigue pattern, its own unit economics. Two UHS facilities in the same tort can sit at different stages. This is the grain at which media buying decisions actually happen.
A $14,000 cost per signed case looks expensive in isolation. A $14,000 cost per signed case on a TT-4 campaign — where the defendant is in resolution posture, settlement frameworks are emerging, and capital horizons are compressing relative to earlier-stage torts — looks like a different investment altogether.
The purpose of TT Stage is to make this translation explicit and standardized. Every campaign rated, every rating tied to a market profile. Capital allocators stop arguing about raw CPSC and start making risk-adjusted decisions — the way every other mature market does.
Bloomberg didn't invent yield. They put yield, duration, credit rating, and maturity on one screen so traders could make risk-adjusted decisions instead of arguing about raw coupon rates.
TT Stage is not a framework imposed on top of the data. It is read from the data. The inputs exist inside Zenith's operational stack because Zenith runs the campaigns that generate them — and no one else does, at this scale, across this many active torts.
Multi-year CPM, CPL, conversion, and creative-level performance across 72+ active campaigns. The ability to detect creative fatigue, audience saturation, and auction pressure in real time — and to distinguish between them. Flat CPM with rising CPL is a sophistication signal no outside observer can see.
Facility-level and defendant-level CPSC trends across the portfolio, normalized for blended spend, per-case fees, and all-in formulas. The truth of what acquisition actually costs at every point in the lifecycle, which becomes the calibration data for stage thresholds.
Defendant-level dossiers built from financial filings, litigation history, insurance coverage, prior settlements, and corporate structure. Multi-agent verification against hallucination. Feeds the litigation-lifecycle side of the rating: who can pay, who has paid, where they are in the resolution arc.
MDL formation, bellwether scheduling, verdict signals, settlement framework announcements, and competitive spend detection across the landscape. The signals that trigger stage transitions are read automatically and surfaced as alerts inside the terminal.
Every campaign surfaced in Tort Terminal carries a TT Stage rating at each level of granularity — tort, defendant, and facility. Partners browsing the opportunity board see the tort-level signal. Clicking through to a tort surfaces defendant-level ratings. Clicking into a defendant surfaces facility-level ratings. Stage transitions trigger alerts. The Capital Face becomes a decision surface instead of a dashboard.
Competitors can photocopy the framework the day this document goes public. None of them can populate it. The inputs that define a stage only exist inside a company that runs the campaigns — which is why TT Stage is not an idea, it is a measurement.
The signals that define a stage — CPM trend, creative fatigue, audience saturation, lead quality drift — only surface when you are in the auction at scale. Outside observers see the newspaper. The rating requires the trading floor.
Once founding firms and institutional funders adopt the vocabulary in their own meetings, Zenith has defined the grammar of litigation finance. Naming rights on the rating system are a generational asset, not a feature.
The rating is not academic. It ties directly to expected IRR, time to cash, and capital fit. That translation layer is what turns raw campaign data into deployable decisions. That is what the subscription is for.